Hemophilia
📧 Sign up to get email alerts when something new happens for Hemophilia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-07Clinical Trial Update: POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies [Phase 4]
A Phase 4 clinical trial investigating hemostatic potential and joint health in severe Hemophilia A patients on novel replacement therapies …
-
CLINICAL_TRIALS withdrawal · 2025-08-29Clinical Trial Update: Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
Pfizer-sponsored clinical trial assessing gene therapy for Hemophilia A and Hemophilia B has been withdrawn from clinicalTrials.gov.
-
EMA withdrawal · 2025-06-04EMA Withdrawn: Beqvez (previously Durveqtix) (fidanacogene elaparvovec) — Pfizer Europe MA EEIG
EMA has withdrawn Beqvez (fidanacogene elaparvovec) for Hemophilia B. The product was previously named Durveqtix and had conditional approva…
-
CLINICAL_TRIALS withdrawal · 2025-03-11Clinical Trial Update: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors [Phase 2]
A Phase 2 study of SerpinPC in participants with Hemophilia B with inhibitors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-12-13Clinical Trial Update: Study of a Gene Therapy Treatment for Hemophilia A [Phase 3]
A Phase 3 gene therapy trial for Hemophilia A sponsored by Spark Therapeutics has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-08-19Clinical Trial Update: A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV) [NA]
A prospective study evaluating seroprevalence and seroconversion of antibodies against adeno-associated virus (AAV) in Hemophilia A patients…
-
CLINICAL_TRIALS withdrawal · 2024-01-05Clinical Trial Update: Emicizumab PUPs and Nuwiq ITI Study [Phase 3]
A Phase 3 clinical trial comparing emicizumab PUPs and Nuwiq ITI has been withdrawn.
-
EMA withdrawal · 2023-03-02EMA Lapsed: Kogenate Bayer (octocog alfa) — Bayer AG
EMA indicates that Kogenate Bayer (octocog alfa) has lapsed (withdrawn) from regulatory status in the European market.
-
EMA withdrawal · 2022-09-27EMA Application withdrawn: HemAryo (eptacog alfa (activated)) — UGA Biopharma
EMA withdrawn the application for HemAryo (eptacog alfa activated) by UGA Biopharma for hemophilia A, hemophilia B, and factor VII deficienc…
-
EMA withdrawal · 2020-06-02EMA Withdrawn: Helixate NexGen (octocog alfa) — Bayer AG
EMA has withdrawn Helixate NexGen (octocog alfa) from the market, with the therapeutic area being Hemophilia A.
-
EMA withdrawal · 2020-02-18EMA Withdrawn: Iblias (octocog alfa) — Bayer AG
The EMA lists Iblias (octocog alfa) as Withdrawn; the therapeutic area is Hemophilia A and the marketing authorization holder is Bayer AG.
-
EMA withdrawal · 2020-02-18EMA Withdrawn: Nonafact (human coagulation factor IX) — Sanquin Plasma Products B.V.
EMA withdrawn the product Nonafact (human coagulation factor IX) for Hemophilia B.
-
CLINICAL_TRIALS withdrawal · 2019-08-20Clinical Trial Update: Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform [Phase 3]
Phase 3 hemophilia inhibitor trials (INHIBIT platform) were withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-09-25Clinical Trial Update: Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A [Phase 4]
A Phase 4 trial comparing blood levels of ReFacto and Advante in Hemophilia A was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-23Clinical Trial Update: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B [Phase 3]
Phase 3 trial of IB1001, a recombinant Factor IX product, for Hemophilia B has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-12-31Clinical Trial Update: Non Neutralizing Antibodies: Prevalence and Characterization
This clinical trial update reports the withdrawal of a study evaluating non-neutralizing antibodies in Hemophilia A.
-
CLINICAL_TRIALS withdrawal · 2014-03-26Clinical Trial Update: Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects [Phase 1]
A Phase 1 bioequivalence trial comparing Eptacog Alfa A 6 mg to NovoSeven in healthy male subjects has been withdrawn.
-
EMA withdrawal · 2013-09-18EMA Application withdrawn: IXinity (trenonacog alfa;trenonacog alfa) — Cangene Europe Limited
The EMA withdrawn the application for IXinity (trenonacog alfa) by Cangene Europe Limited in the therapeutic area of Hemophilia B.
-
CLINICAL_TRIALS withdrawal · 2012-06-28Clinical Trial Update: Study Evaluating Inhibitor Specificity in Hemophilia A [Phase 4]
A Phase 4 clinical trial evaluating inhibitor specificity in Hemophilia A has been withdrawn.